Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
VIRALEZE Nasal Spray to be distributed in Hong Kong and Macau 2022-10-25 08:13
Starpharma presents compelling data in Prostate Cancer at ESMO 2022-09-13 06:28
Starpharma signs new DEP® agreement with MSD 2022-08-10 15:29
VIRALEZE™ Nasal Spray Protects Against Highly Infectious Omicron in Viral Challenge Model - Before or After Viral Exposure 2022-07-20 17:45
Australian developed VIRALEZE™ nasal spray relaunched by LloydsPharmacy in the UK 2022-06-30 12:41
Active agent in Australian-developed nasal spray >99.5% active against the Omicron SARS-CoV-2 variant 2022-03-01 16:44
Starpharma signs distribution agreement for VIRALEZE™ antiviral nasal spray in Vietnam 2021-12-03 14:24
VIRALEZE™ antiviral nasal spray registered in Vietnam with launch to follow this week 2021-12-01 16:40
Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel 2021-11-26 17:34
Starpharma releases positive DEP® phase 2 interim results in prostate cancer 2021-11-26 15:41
VIRALEZE™ antiviral nasal spray launched in ADMENTA Italia Group pharmacies in Italy 2021-10-08 13:51
US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments 2021-09-15 15:27
Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model 2021-08-23 20:23
VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant 2021-07-27 19:53
Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants 2021-06-18 14:16
Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants 2021-06-18 14:04
Viraleze registered for sale in Covid-ravaged India 2021-06-11 15:15
1